Dr. Lal Path Labs profit and loss

Latest FY26

Revenue: ₹2,763cr+12.2% on FY25
EBITDA: ₹783cr+12.5% on FY25
Net profit: ₹510cr+3.6% on FY25
EPS: ₹30.24−48.3% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Expenses
	2,891	2,763	2,461	2,227	2,017	FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	105	101	93.4	69.2	41.7
	2,996	2,864	2,555	2,296	2,059
	557	535	482	451	447
	528	503	482	425	377
	24.4	22.8	22.3	29.4	37.5
	172	162	142	144	150
	968	943	802	741	703
	2,249	2,165	1,930	1,790	1,715
	838	783	696	609	490
	666	621	554	466	340
Profit
	747	699	625	506	344
	−30.1	−30.1	0.0	0.0	0.0
	717	669	625	506	344
	174	159	172	148	108
	−3.5	0.1	−39.5	−4.8	−5.1
	170	159	133	143	103
	546	510	492	362	241
	546	510	492	362	241
	7.5	5.2	−3.6	−0.6	1.6
	554	515	489	362	243
	542	505	487	358	239
	4.4	5.0	5.1	4.6	2.2
Per share
	₹41.48	₹30.24	₹58.48	₹43.05	₹28.82
	₹41.40	₹30.20	₹58.40	₹42.98	₹28.74
Other comprehensive income — detail
	7.5	5.2	−3.6	—	—
	9.6	6.7	−4.9	−0.5	2.6
	2.4	1.7	−1.3	—	—
	—	—	—	−0.1	0.6
	0.3	0.2	0.0	−0.2	−0.4
	549	510	484	357	241
	4.4	5.0	5.1	4.5	2.2
Per share — as-filed variants
	₹41.48	₹30.24	₹58.48	₹43.05	₹28.82
	₹41.40	₹30.20	₹58.40	₹42.98	₹28.74
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	2,333	2,228	1,980	1,775	1,570
	80.7%	80.7%	80.4%	79.7%	77.8%
Adjusted (ex-exceptional items) — derived
	747	699	625	506	344
	−30.1	−30.1	0.0	0.0	0.0
	569	533	492	362	241
	₹43.22	₹31.60	₹58.48	₹43.05	₹28.82

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

LALPATHLAB₹1,911.70

Dr. Lal Path Labs Ltd.

· Pharma & Health

Annual Quarterly₹ CrorePeersMETROPOLIS VIJAYA THYROCARE NATCOPHARM NEULANDLAB NH COHANCE SAILIFEMcap ₹32,040 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	2,016.9	2,226.6	2,461.4	2,762.9	2,890.8
Other Income	41.7	69.2	93.4	101.3	105.1
Total Income	2,058.6	2,295.8	2,554.8	2,864.2	2,995.9
Expenses
+ Cost of Materials Consumed	447.2	451.4	481.5	534.6	557.4
+ Employee Benefit Expense	376.5	424.5	482.4	503.3	528.2
+ Finance Costs	37.5	29.4	22.3	22.8	24.4
+ Depreciation & Amortisation	150.2	143.6	141.9	161.8	171.6
+ Other Expenses	703.3	741.4	802.0	942.5	967.5
Total Expenses	1,714.7	1,790.3	1,930.1	2,165.0	2,249.1
EBITDA	489.9	609.3	695.5	782.5	837.7
EBIT	339.7	465.7	553.6	620.7	666.1
Profit
PBT before Exceptional Items	343.9	505.5	624.7	699.2	746.8
+ Exceptional Items	0.0	0.0	0.0	-30.1	-30.1
Pretax Income	343.9	505.5	624.7	669.1	716.7
+ Current Tax	107.9	148.0	172.0	159.2	173.9
+ Deferred Tax	-5.1	-4.8	-39.5	0.1	-3.5
Tax Expense	102.8	143.2	132.5	159.3	170.4
Net Income	241.1	362.3	492.2	509.8	546.3
+ Net Income — Continuing Ops	241.1	362.3	492.2	509.8	546.3
+ Other Comprehensive Income	1.6	-0.6	-3.6	5.2	7.5
Total Comprehensive Income	242.7	361.7	488.6	515.0	553.8
Net Income to Common	238.9	357.7	487.1	504.8	541.9
Minority Interest	2.2	4.6	5.1	5.0	4.4
Per Share
Basic EPS	28.82	43.05	58.48	30.24	41.48
Diluted EPS	28.74	42.98	58.40	30.20	41.40
Other Comprehensive Income — detail
+ Other Comprehensive Income	—	—	-3.6	5.2	7.5
+ Items NOT to be Reclassified to P&L	2.6	-0.5	-4.9	6.7	9.6
+ Tax on Items NOT to be Reclassified	—	—	-1.3	1.7	2.4
+ Tax on Items NOT to be Reclassified — alt tag	0.6	-0.1	—	—	—
+ Items to be Reclassified to P&L	-0.4	-0.2	0.0	0.2	0.3
Comprehensive Income — Owners of Parent	240.5	357.2	483.5	510.0	549.4
Comprehensive Income — Non-controlling Interests	2.2	4.5	5.1	5.0	4.4
Per Share — as-filed variants
Basic EPS — Continuing Operations	28.82	43.05	58.48	30.24	41.48
Diluted EPS — Continuing Operations	28.74	42.98	58.40	30.20	41.40
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	1,569.7	1,775.2	1,979.9	2,228.3	2,333.4
Gross Margin %	77.83	79.73	80.44	80.65	80.72
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	343.9	505.5	624.7	699.2	746.8
− Exceptional Items (reconciliation)	0.0	0.0	0.0	-30.1	-30.1
Net Income Adj (tax-effected)	241.1	362.3	492.2	532.7	569.2
EPS Adj	28.82	43.05	58.48	31.60	43.22
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	10.00	10.00	10.00	10.00	10.00
Paid Up Equity Capital	83.4	83.5	83.6	167.6	167.6

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.